Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021
![](/report_cover/2671/diabetic-foot-ulcers-metabolic-disorder-drugs-in-development-2021_en.gif)
Diabetic Foot Ulcers (Metabolic Disorder) - Drugs in Development, 2021
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 20, 10, 2, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 20, 10, 2, 17, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Diabetic Foot Ulcers - Overview
Diabetic Foot Ulcers - Therapeutics Development
Diabetic Foot Ulcers - Therapeutics Assessment
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
Diabetic Foot Ulcers - Drug Profiles
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Appendix
Diabetic Foot Ulcers - Overview
Diabetic Foot Ulcers - Therapeutics Development
Diabetic Foot Ulcers - Therapeutics Assessment
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
Diabetic Foot Ulcers - Drug Profiles
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Diabetic Foot Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Diabetic Foot Ulcers - Pipeline by Alan Laboratories Inc, 2021
Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Aposcience AG, 2021
Diabetic Foot Ulcers - Pipeline by Aprogen Inc, 2021
Diabetic Foot Ulcers - Pipeline by APstem Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by AptaBio Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Aurealis Therapeutics AG, 2021
Diabetic Foot Ulcers - Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Biofilm Pharma, 2021
Diabetic Foot Ulcers - Pipeline by Blue Blood Biotech Corp, 2021
Diabetic Foot Ulcers - Pipeline by Canton Biotechnologies Inc, 2021
Diabetic Foot Ulcers - Pipeline by Cellics Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Cellresearch Corp Pte Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Celularity Inc, 2021
Diabetic Foot Ulcers - Pipeline by Chiesi Farmaceutici SpA, 2021
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Crescita Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by CSA Biotechnologies LLC, 2021
Diabetic Foot Ulcers - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021
Diabetic Foot Ulcers - Dormant Projects, 2021
Diabetic Foot Ulcers - Discontinued Products, 2021
Number of Products under Development for Diabetic Foot Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Diabetic Foot Ulcers - Pipeline by Alan Laboratories Inc, 2021
Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Aposcience AG, 2021
Diabetic Foot Ulcers - Pipeline by Aprogen Inc, 2021
Diabetic Foot Ulcers - Pipeline by APstem Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by AptaBio Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Aurealis Therapeutics AG, 2021
Diabetic Foot Ulcers - Pipeline by Beijing Huafeng Biotechnology Co Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Biofilm Pharma, 2021
Diabetic Foot Ulcers - Pipeline by Blue Blood Biotech Corp, 2021
Diabetic Foot Ulcers - Pipeline by Canton Biotechnologies Inc, 2021
Diabetic Foot Ulcers - Pipeline by Cellics Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Cellresearch Corp Pte Ltd, 2021
Diabetic Foot Ulcers - Pipeline by Celularity Inc, 2021
Diabetic Foot Ulcers - Pipeline by Chiesi Farmaceutici SpA, 2021
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by Crescita Therapeutics Inc, 2021
Diabetic Foot Ulcers - Pipeline by CSA Biotechnologies LLC, 2021
Diabetic Foot Ulcers - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021
Diabetic Foot Ulcers - Dormant Projects, 2021
Diabetic Foot Ulcers - Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development for Diabetic Foot Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
Number of Products under Development for Diabetic Foot Ulcers, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021